The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could lead to a positive short-term impact on Trevi Therapeutics' stock price. The specific mention of the company and the reaffirmation of the price target suggest a strong belief in the company's potential, making this news highly relevant and important for investors in TRVI.